insights_auto
Why is DRREDDY up 2,71%?
Dive Deeperchevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 229,40 ₹
arrow_upward
+2,71%(+32,40) 1D
12 қаз., 15:30:00 GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
1 197,00 ₹
High
1 235,00 ₹
Low
1 196,90 ₹
Mkt. cap
1,02 трлн
Avg. vol.
1,79 млн
Volume
1,76 млн
Dividend
0,65%
Quarterly dividend
2,00 ₹
Ex-dividend date
2026 ж. 10 шіл.
P/E ratio
31,79
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 млн
No. of employees
28 мың
Open
1 197,00 ₹
High
1 235,00 ₹
Low
1 196,90 ₹
Mkt. cap
1,02 трлн
Avg. vol.
1,79 млн
Volume
1,76 млн
Dividend
0,65%
Quarterly dividend
2,00 ₹
Ex-dividend date
2026 ж. 10 шіл.
P/E ratio
31,79
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 млн
No. of employees
28 мың
News stories
From web sources and news partners
GlobeNewswire
·
26 минут бұрын
Stewards Inc. to Ring Nasdaq Opening Bell on Oct. 14, Celebrating Company's Next Chapter
PR Newswire
·
26 минут бұрын
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IPO Edge
·
9 минут бұрын
Targeting Water Scarcity: Rain Enhancement Technologies CEO Randy Seidl, Live at Nasdaq
Yahoo Finance
·
20 минут бұрын
A handful of tech stocks are masking an ugly S&P 500 problem
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 мың
Founded1984
HeadquartersХайдарабад, Андхра-Прадеш, Үндістан
SectorPharmaceutical industry
Websitedrreddys.com